Engineered nanoparticles mimicking cell membranes for toxin neutralization

Advanced Drug Delivery Reviews

Volumn 90, Issue , 2015, Pages 69-80

  Fang, Ronnie H ^a   Luk, Brian T ^a   Hu, Che Ming J ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Anti toxin nanoparticles; Cell membranes; Detoxification; Liposomes; Nanosponges; Virulence factors

Indexed keywords

BACTERIA; CELL MEMBRANES; CELLS; DETOXIFICATION; LIPOSOMES; MEMBRANES; METABOLITES; MOBILE SECURITY; NANOPARTICLES; TOXIC MATERIALS;

CELLULAR MEMBRANES; ENGINEERED NANOPARTICLES; MEMBRANE INTERFACE; NANOPARTICULATES; NANOSPONGES; PATHOGENIC BACTERIUM; STRUCTURAL SIMILARITY; VIRULENCE FACTORS;

CYTOLOGY;

BINDING PROTEIN; CARBOHYDRATES AND CARBOHYDRATE DERIVATIVES; CHOLESTEROL; LIPID DERIVATIVE; LIPOPROTEIN; LIPOSOME; MEMBRANE PROTEIN; NANOPARTICLE; TETANUS TOXOID; TOXIN; UNCLASSIFIED DRUG; ANTITOXIN; TOXOID; VACCINE;

BINDING AFFINITY; BINDING SITE; CELL ENGINEERING; CELL MEMBRANE; CHEMICAL BINDING; CHEMICAL STRUCTURE; DETOXIFICATION; HUMAN; LIPID MEMBRANE; MEMBRANE STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NANOANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STATIC ELECTRICITY; STRUCTURE ANALYSIS; TOXIN ANALYSIS; TYPE III SECRETION SYSTEM; ANIMAL; DRUG THERAPY; INTOXICATION; METABOLISM; VIRULENCE;

ANIMALS; ANTITOXINS; CELL MEMBRANE; HUMANS; NANOPARTICLES; POISONING; TOXINS, BIOLOGICAL; TOXOIDS; VACCINES; VIRULENCE;

EID: 84939576078     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.04.001     Document Type: Review

References (158)

1. Nelsen D.R., Nisani Z., Cooper A.M., Fox G.A., Gren E.C.K., Corbit A.G., Hayes W.K. Poisons, toxungens, and venoms: redefining and classifying toxic biological secretions and the organisms that employ them. Biol. Rev. 2014, 89:450-465.
2. Henkel J.S., Baldwin M.R., Barbieri J.T. Toxins from bacteria. Experientia Suppl. 2010, 100:1-29.
3. Fry B.G., Roelants K., Champagne D.E., Scheib H., Tyndall J.D.A., King G.F., Nevalainen T.J., Norman J.A., Lewis R.J., Norton R.S., Renjifo C., de la Vega R.C.R. The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu. Rev. Genomics Hum. Genet. 2009, 10:483-511.
4. Howard D.H., Scott R.D., Packard R., Jones D. The global impact of drug resistance. Clin. Infect. Dis. 2003, 36:S4-S10.
5. White J. Bites and stings from venomous animals: a global overview. Ther. Drug Monit. 2000, 22:65-68.
6. Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., Hauer J., McDade J., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Tonat K., Biodefense W.G.C. Anthrax as a biological weapon - medical and public health management. J. Am. Med. Assoc. 1999, 281:1735-1745.
7. Rasko D.A., Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 2010, 9:117-128.
8. Cegelski L., Marshall G.R., Eldridge G.R., Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 2008, 6:17-27.
9. Guerrant R.L., Steiner T.S., Lima A.A.M., Bobak D.A. How intestinal bacteria cause disease. J. Infect. Dis. 1999, 179:S331-S337.
10. Mellbye B., Schuster M. The sociomicrobiology of antivirulence drug resistance: a proof of concept. MBio 2011, 2:e00131-11.
11. Nikaido H. Multidrug resistance in bacteria. Annu. Rev. Biochem. 2009, 78:119-146.
12. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74:417-433.
13. Rainey G.J.A., Young J.A.T. Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. 2004, 2:721-726.
14. Hussack G., Tanha J. Toxin-specific antibodies for the treatment of clostridium difficile: current status and future perspectives. Toxins 2010, 2:998-1018.
15. Vassilevski A.A., Kozlov S.A., Grishin E.V. Molecular diversity of spider venom. Biochem. Mosc. 2009, 74:1505-1534.
16. de Maagd R.A., Bravo A., Berry C., Crickmore N., Schnepf H.E. Structure, diversity, and evolution of protein toxins from spore-forming entomopathogenic bacteria. Annu. Rev. Genet. 2003, 37:409-433.
17. Hu C.M.J., Fang R.H., Copp J., Luk B.T., Zhang L.F. A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nanotechnol. 2013, 8:336-340.
18. Henry B.D., Neill D.R., Becker K.A., Gore S., Bricio-Moreno L., Ziobro R., Edwards M.J., Muhlemann K., Steinmann J., Kleuser B., Japtok L., Luginbuhl M., Wolfmeier H., Scherag A., Gulbins E., Kadioglu A., Draeger A., Babiychuk E.B. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat. Biotechnol. 2014, 33:81-88.
19. Geny B., Popoff M.R. Bacterial protein toxins and lipids: pore formation or toxin entry into cells. Biol. Cell. 2006, 98:667-678.
20. Reig N., van der Goot F.G. About lipids and toxins. FEBS Lett. 2006, 580:5572-5579.
21. Fishman P.H. Role of membrane gangliosides in the binding and action of bacterial toxins. J. Membr. Biol. 1982, 69:85-97.
22. Eidels L., Proia R.L., Hart D.A. Membrane-receptors for bacterial toxins. Microbiol. Rev. 1983, 47:596-620.
23. Youle R.J., Murray G.J., Neville D.M. Ricin linked to monophosphopentamannose binds to fibroblast lysosomal hydrolase receptors, resulting in a cell-type-specific toxin. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:5559-5562.
24. Mccleskey E.W., Fox A.P., Feldman D.H., Cruz L.J., Olivera B.M., Tsien R.W., Yoshikami D. Omega-conotoxin - direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:4327-4331.
25. Wilke G.A., Wardenburg J.B. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13473-13478.
26. Mouhat S., Andreotti N., Jouirou B., Sabatier J.M. Animal toxins acting on voltage-gated potassium channels. Curr. Pharm. Des. 2008, 14:2503-2518.
27. Cowell S., Aschauer W., Gruber H.J., Nelson K.L., Buckley J.T. The erythrocyte receptor for the channel-forming toxin aerolysin is a novel glycosylphosphatidylinositol-anchored protein. Mol. Microbiol. 1997, 25:343-350.
28. Abrami L., van der Goot F.G. Plasma membrane microdomains act as concentration platforms to facilitate intoxication by aerolysin. J. Cell Biol. 1999, 147:175-184.
29. Young J.A.T., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76:243-265.
30. Valentin E., Lambeau G. What can venom phospholipases A(2) tell us about the functional diversity of mammalian secreted phospholipases A(2)?. Biochimie 2000, 82:815-831.
31. Holmgren J., Lonnroth I., Mansson J.E., Svennerholm L. Interaction of cholera toxin and membrane Gm1 ganglioside of small-intestine. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:2520-2524.
32. Helting T.B., Zwisler O. Structure of tetanus toxin. 1. Breakdown of toxin molecule and discrimination between polypeptide fragments. J. Biol. Chem. 1977, 252:187-193.
33. Svennerholm A.M., Holmgren J. Identification of Escherichia-coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (Gm1-Elisa) procedure. Curr. Microbiol. 1978, 1:19-23.
34. Lingwood C.A., Law H., Richardson S., Petric M., Brunton J.L., Degrandis S., Karmali M. Glycolipid binding of purified and recombinant Escherichia-coli produced verotoxin invitro. J. Biol. Chem. 1987, 262:8834-8839.
35. Obrig T.G., Louise C.B., Lingwood C.A., Boyd B., Barleymaloney L., Daniel T.O. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 1993, 268:15484-15488.
36. Ewers H., Helenius A. Lipid-mediated endocytosis. CHS Perspect. Biol. 2011, 3:a004721.
37. Yamaji A., Sekizawa Y., Emoto K., Sakuraba H., Inoue K., Kobayashi H., Umeda M. Lysenin, a novel sphingomyelin-specific binding protein. J. Biol. Chem. 1998, 273:5300-5306.
38. Yamaji-Hasegawa A., Makino A., Baba T., Senoh Y., Kimura-Suda H., Sato S.B., Terada N., Ohno S., Kiyokawa E., Umeda M., Kobayashi T. Oligomerization and pore formation of a sphingomyelin-specific toxin, lysenin. J. Biol. Chem. 2003, 278:22762-22770.
39. Garcia P., Gupta R., Shah S., Morris A.J., Rudge S.A., Scarlata S., Petrova V., McLaughlin S., Rebecchi M.J. The pleckstrin homology domain of phospholipase C-delta(1) binds with high affinity to phosphatidylinositol 4,5-bisphosphate in bilayer membranes. Biochemistry 1995, 34:16228-16234.
40. Mosior M., Six D.A., Dennis E.A. Group IV cytosolic phospholipase A(2) binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity. J. Biol. Chem. 1998, 273:2184-2191.
41. Schmiel D.H., Miller V.L. Bacterial phospholipases and pathogenesis. Microbes Infect. 1999, 1:1103-1112.
42. Shipolin R.A., Callewae G.L., Cottrell R.C., Doonan S., Vernon C.A., Banks B.E.C. Phospholipase-a from bee venom. Eur. J. Biochem. 1971, 20:459-468.
43. Dennis E.A., Darke P.L., Deems R.A., Kensil C.R., Pluckthun A. Cobra venom phospholipase-A2 - a review of its action toward lipid-water interfaces. Mol. Cell. Biochem. 1981, 36:37-45.
44. Palmer M. Cholesterol and the activity of bacterial toxins. FEMS Microbiol. Lett. 2004, 238:281-289.
45. Tweten R.K. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect. Immun. 2005, 73:6199-6209.
46. Ohno-Iwashita Y., Shimada Y., Waheed A.A., Hayashi M., Inomata M., Nakamura M., Maruya M., Iwashita S. Perfringolysin O, a cholesterol-binding cytolysin, as a probe for lipid rafts. Anaerobe 2004, 10:125-134.
47. Farrand A.J., LaChapelle S., Hotze E.M., Johnson A.E., Tweten R.K. Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4341-4346.
48. Harris J.R., Palmer M. Cholesterol specificity of some heptameric beta-barrel pore-forming bacterial toxins: structural and functional aspects. Subcell. Biochem. 2010, 51:579-596.
49. Miyata S., Minami J., Tamai E., Matsushita O., Shimamoto S., Okabe A. Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J. Biol. Chem. 2002, 277:39463-39468.
50. Verheij H.M., Boffa M.C., Rothen C., Bryckaert M.C., Verger R., Dehaas G.H. Correlation of enzymatic-activity and anti-coagulant properties of phospholipase-A2. Eur. J. Biochem. 1980, 112:25-32.
51. Diaz C., Leon G., Rucavado A., Rojas N., Schroit A.J., Gutierrez J.M. Modulation of the susceptibility of human erythrocytes to snake venom myotoxic phospholipases A(2): role of negatively charged phospholipids as potential membrane binding sites. Arch. Biochem. Biophys. 2001, 391:56-64.
52. Scott D.L., Mandel A.M., Sigler P.B., Honig B. The electrostatic basis for the interfacial binding of secretary phospholipases a(2). Biophys. J. 1994, 67:493-504.
53. Huang X.Q., Dong F., Zhou H.X. Electrostatic recognition and induced fit in the k-PVIIA toxin binding to Shaker potassium channel. J. Am. Chem. Soc. 2005, 127:6836-6849.
54. Hall K., Lee T.H., Aguilar M.I. The role of electrostatic interactions in the membrane binding of melittin. J. Mol. Recognit. 2011, 24:108-118.
55. Gonzalez M.R., Bischofberger M., Pernot L., van der Goot F.G., Freche B. Bacterial pore-forming toxins: the (w)hole story?. Cell. Mol. Life Sci. 2008, 65:493-507.
56. Gouaux E. Alpha-hemolysin from Staphylococcus aureus: an archetype of beta-barrel, channel-forming toxins. J. Struct. Biol. 1998, 121:110-122.
57. Parker M.W., van der Goot F.G., Buckley J.T. Aerolysin - the ins and outs of a model channel-forming toxin. Mol. Microbiol. 1996, 19:205-212.
58. Pantano S., Montecucco C. A molecular model of the Vibrio cholerae cytolysin transmembrane pore. Toxicon 2006, 47:35-40.
59. Tilley S.J., Saibil H.R. The mechanism of pore formation by bacterial toxins. Curr. Opin. Struct. Biol. 2006, 16:230-236.
60. Abrami L., Fivaz M., Decroly E., Seidah N.G., Jean F., Thomas G., Leppla S.H., Buckley J.T., van der Goot F.G. The pore-forming toxin proaerolysin is activated by furin. J. Biol. Chem. 1998, 273:32656-32661.
61. Nguyen V.T., Kamio Y. Cooperative assembly of beta-barrel pore-forming toxins. J. Biochem. 2004, 136:563-567.
62. Forouhar F., Huang W.N., Liu J.H., Chien K.Y., Wu W.G., Hsiao C.D. Structural basis of membrane-induced cardiotoxin A3 oligomerization. J. Biol. Chem. 2003, 278:21980-21988.
63. Lee M.T., Sun T.L., Hung W.C., Huang H.W. Process of inducing pores in membranes by melittin. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:14243-14248.
64. Thomas R.G., Pough F.H. Effect of rattlesnake venom on digestion of prey. Toxicon 1979, 17:221-228.
65. O'Brien D.K., Melville S.B. Effects of Clostridium perfringens alpha-toxin (PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the phagosomes of macrophages, and on persistence of C-perfringens in host tissues. Infect. Immun. 2004, 72:5204-5215.
66. Berstad A.E., Berstad K., Berstad A. pH-activated phospholipase A(2): an important mucosal barrier breaker in peptic ulcer disease. Scand. J. Gastroenterol. 2002, 37:738-742.
67. Ghannoum M.A. Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev. 2000, 13:122-143.
68. Proft T., Fraser J.D. Bacterial superantigens. Clin. Exp. Immunol. 2003, 133:299-306.
69. Webb S.R., Gascoigne N.R.J. T-cell activation by superantigens. Curr. Opin. Immunol. 1994, 6:467-475.
70. Spaulding A.R., Salgado-Pabon W., Kohler P.L., Horswill A.R., Leung D.Y.M., Schlievert P.M. Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 2013, 26:422-447.
71. Field M., Graf L.H., Laird W.J., Smith P.L. Heat-stable enterotoxin of Escherichia-coli - invitro effects on guanylate cyclase activity, cyclic-Gmp concentration, and ion-transport in small-intestine. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:2800-2804.
72. Nirthanan S., Gwee M.C.E. Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on. J. Pharmacol. Sci. 2004, 94:1-17.
73. Barber C.M., Isbister G.K., Hodgson W.C. Alpha neurotoxins. Toxicon 2013, 66:47-58.
74. Karlsson E., Mbugua P.M., Rodriguezithurralde D. Fasciculins, anticholinesterase toxins from the venom of the green mamba Dendroaspis-angusticeps. J. Physiol. Paris 1984, 79:232-240.
75. Stevens M., Peigneur S., Tytgat J. Neurotoxins and their binding areas on voltage-gated sodium channels. Front. Pharmacol. 2011, 2:71.
76. Sousa S.R., Vetter I., Lewis R.J. Venom peptides as a rich source of Ca(v)2.2 channel blockers. Toxins 2013, 5:286-314.
77. Restrepo-Angulo I., De Vizcaya-Ruiz A., Camacho J. Ion channels in toxicology. J. Appl. Toxicol. 2010, 30:497-512.
78. Debin J.A., Maggio J.E., Strichartz G.R. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am. J. Physiol. 1993, 264:C361-C369.
79. Harvey A.L., Karlsson E. Dendrotoxin from the venom of the green mamba, Dendroaspis-angusticeps - a neurotoxin that enhances acetylcholine-release at neuromuscular-junctions. Naunyn Schmiedeberg's Arch. Pharmacol. 1980, 312:1-6.
80. Chau R., Kalaitzis J.A., Neilan B.A. On the origins and biosynthesis of tetrodotoxin. Aquat. Toxicol. 2011, 104:61-72.
81. Ovchinnikov Y.A., Grishin E.V. Scorpion neurotoxins as tools for studying fast sodium-channels. Trends Biochem. Sci. 1982, 7:26-28.
82. Veneziano R., Rossi C., Chenal A., Devoisselle J.M., Ladant D., Chopineau J. Bordetella pertussis adenylate cyclase toxin translocation across a tethered lipid bilayer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20473-20478.
83. Barth H., Aktories K., Popoff M.R., Stiles B.G. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev. 2004, 68:373-402.
84. Murphy J.R. Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxins 2011, 3:294-308.
85. Spooner R.A., Smith D.C., Easton A.J., Roberts L.M., Lord J.M. Retrograde transport pathways utilised by viruses and protein toxins. Virol. J. 2006, 3.
86. Johannes L., Romer W. Shiga toxins - from cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8:105-116.
87. Lord J.M., Roberts L.M., Robertus J.D. Ricin: structure, mode of action, and some current applications. FASEB J. 1994, 8:201-208.
88. Lencer W.I., Hirst T.R., Holmes R.K. Membrane traffic and the cellular uptake of cholera toxin. Biochim. Biophys. Acta 1999, 1450:177-190.
89. Spooner R.A., Lord J.M. How ricin and Shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum. Curr. Top. Microbiol. 2012, 357:19-40.
90. Veenendaal A.K.J., Hodgkinson J.L., Schwarzer L., Stabat D., Zenk S.F., Blocker A.J. The type III secretion system needle tip complex mediates host cell sensing and translocon insertion. Mol. Microbiol. 2007, 63:1719-1730.
91. Hayward R.D., Cain R.J., McGhie E.J., Phillips N., Garner M.J., Koronakis V. Cholesterol binding by the bacterial type III translocon is essential for virulence effector delivery into mammalian cells. Mol. Microbiol. 2005, 56:590-603.
92. Shen D.K., Saurya S., Wagner C., Nishioka H., Blocker A.J. Domains of the Shigella flexneri type III secretion system IpaB protein involved in secretion regulation. Infect. Immun. 2010, 78:4999-5010.
93. Coburn B., Sekirov I., Finlay B.B. Type III secretion systems and disease. Clin. Microbiol. Rev. 2007, 20:535-549.
94. Bangham A.D., Standish M.M., Weissmann G. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J. Mol. Biol. 1965, 13:253-259.
95. Weissmann G., Sessa G., Bernheimer A.W. Staphylococcal alpha-toxin: effects on artificial lipid spherules. Science 1966, 154:772-774.
96. Duncan J.L., Schlegel R. Effect of streptolysin O on erythrocyte membranes, liposomes, and lipid dispersions. A protein-cholesterol interaction. J. Cell Biol. 1975, 67:160-174.
97. Alving C.R., Iglewski B.H., Urban K.A., Moss J., Richards R.L., Sadoff J.C. Binding of diphtheria toxin to phospholipids in liposomes. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:1986-1990.
98. Kagan B.L., Finkelstein A., Colombini M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:4950-4954.
99. Alonso A., Goni F.M., Buckley J.T. Lipids favoring inverted phase enhance the ability of aerolysin to permeabilize liposome bilayers. Biochemistry 2000, 39:14019-14024.
100. Tilley S.J., Orlova E.V., Gilbert R.J., Andrew P.W., Saibil H.R. Structural basis of pore formation by the bacterial toxin pneumolysin. Cell 2005, 121:247-256.
101. Cowell J.L., Bernheimer A.W. Role of cholesterol in the action of cereolysin on membranes. Arch. Biochem. Biophys. 1978, 190:603-610.
102. Alving C.R., Habig W.H., Urban K.A., Hardegree M.C. Cholesterol-dependent tetanolysin damage to liposomes. Biochim. Biophys. Acta 1979, 551:224-228.
103. Bougis P., Rochat H., Pieroni G., Verger R. Penetration of phospholipid monolayers by cardiotoxins. Biochemistry 1981, 20:4915-4920.
104. Sessa G., Freer J.H., Colacicco G., Weissmann G. Interaction of alytic polypeptide, melittin, with lipid membrane systems. J. Biol. Chem. 1969, 244:3575-3582.
105. Nagahama M., Michiue K., Sakurai J. Membrane-damaging action of Clostridium perfringens alpha-toxin on phospholipid liposomes. Biochim. Biophys. Acta 1996, 1280:120-126.
106. Shogomori H., Kobayashi T. Lysenin: a sphingomyelin specific pore-forming toxin. Biochim. Biophys. Acta 2008, 1780:612-618.
107. Singh A.K., Harrison S.H., Schoeniger J.S. Gangliosides as receptors for biological toxins: development of sensitive fluoroimmunoassays using ganglioside-bearing liposomes. Anal. Chem. 2000, 72:6019-6024.
108. Pan J.J., Charych D. Molecular recognition and colorimetric detection of cholera toxin by poly(diacetylene) liposomes incorporating G(m1) ganglioside. Langmuir 1997, 13:1365-1367.
109. Alfonta L., Willner I., Throckmorton D.J., Singh A.K. Electrochemical and quartz crystal microbalance detection of the cholera toxin employing horseradish peroxidase and GM1-functionalized liposomes. Anal. Chem. 2001, 73:5287-5295.
110. Ahn-Yoon S., DeCory T.R., Baeumner A.J., Durst R.A. Ganglioside-liposome immunoassay for the ultrasensitive detection of cholera toxin. Anal. Chem. 2003, 75:2256-2261.
111. Pornpattananangkul D., Zhang L., Olson S., Aryal S., Obonyo M., Vecchio K., Huang C.M., Zhang L.F. Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J. Am. Chem. Soc. 2011, 133:4132-4139.
112. Cheong I., Huang X., Bettegowda C., Diaz L.A., Kinzler K.W., Zhou S., Vogelstein B. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006, 314:1308-1311.
113. Thamphiwatana S., Gao W.W., Pornpattananangkul D., Zhang Q.Z., Fu V., Li J.Y., Li J.M., Obonyo M., Zhang L.F. Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection. J. Mater. Chem. B 2014, 2:8201-8207.
114. Zolnik B.S., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M.A. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
115. Basha S., Rai P., Poon V., Saraph A., Gujraty K., Go M.Y., Sadacharan S., Frost M., Mogridge J., Kane R.S. Polyvalent inhibitors of anthrax toxin that target host receptors. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13509-13513.
116. Lingwood D., Simons K. Lipid rafts as a membrane-organizing principle. Science 2010, 327:46-50.
117. Malmendier C.L., Delcroix C., Ameryckx J.P. In vivo metabolism of human apoprotein A-I-phospholipid complexes. Comparison with human high density lipoprotein-apoprotein A-I metabolism. Clin. Chim. Acta 1983, 131:201-210.
118. Whorton M.R., Bokoch M.P., Rasmussen S.G., Huang B., Zare R.N., Kobilka B., Sunahara R.K. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7682-7687.
119. Bricarello D.A., Smilowitz J.T., Zivkovic A.M., German J.B., Parikh A.N. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano 2011, 5:42-57.
120. Bayburt T.H., Leitz A.J., Xie G., Oprian D.D., Sligar S.G. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. J. Biol. Chem. 2007, 282:14875-14881.
121. Cappuccio J.A., Hinz A.K., Kuhn E.A., Fletcher J.E., Arroyo E.S., Henderson P.T., Blanchette C.D., Walsworth V.L., Corzett M.H., Law R.J., Pesavento J.B., Segelke B.W., Sulchek T.A., Chromy B.A., Katzen F., Peterson T., Bench G., Kudlicki W., Hoeprich P.D., Coleman M.A. Cell-free expression for nanolipoprotein particles: building a high-throughput membrane protein solubility platform. Methods Mol. Biol. 2009, 498:273-296.
122. Baker S.E., Hopkins R.C., Blanchette C.D., Walsworth V.L., Sumbad R., Fischer N.O., Kuhn E.A., Coleman M., Chromy B.A., Letant S.E., Hoeprich P.D., Adams M.W., Henderson P.T. Hydrogen production by a hyperthermophilic membrane-bound hydrogenase in water-soluble nanolipoprotein particles. J. Am. Chem. Soc. 2009, 131:7508-7509.
123. Bayburt T.H., Sligar S.G. Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers. Protein Sci. 2003, 12:2476-2481.
124. Seganti L., Valenti P., Mastromarino P., Sinibaldi L., De Stasio A., Orsi N. Inhibition of staphylococcal beta-hemolysin by human serum lipoproteins and their components. Ann. Sclavo 1980, 22:719-728.
125. Badin J., Barillec A. Streptolysin O inhibition by serum gamma G-globulin and beta-lipoprotein after blocking of nonesterified cholesterol by digitonin. J. Lab. Clin. Med. 1970, 75:975-982.
126. Fukuchi Y., Kudo Y., Kumagai T., Ebina K., Yokota K. Oxidized low density lipoprotein inhibits the hemolytic activity of Asp-hemolysin from Aspergillus fumigatus. FEMS Microbiol. Lett. 1998, 167:275-280.
127. Bernheimer A.W., Avigad L.S. Properties of a toxin from the sea anemone Stoichacis helianthus, including specific binding to sphingomyelin. Proc. Natl. Acad. Sci. U. S. A. 1976, 73:467-471.
128. Bricarello D.A., Mills E.J., Petrlova J., Voss J.C., Parikh A.N. Ganglioside embedded in reconstituted lipoprotein binds cholera toxin with elevated affinity. J. Lipid Res. 2010, 51:2731-2738.
129. Lauer S., Goldstein B., Nolan R.L., Nolan J.P. Analysis of cholera toxin-ganglioside interactions by flow cytometry. Biochemistry 2002, 41:1742-1751.
130. Sheng J.R., Grimme S., Bhattacharya P., Stowell M.H., Artinger M., Prabahakar B.S., Meriggioli M.N. In vivo adsorption of autoantibodies in myasthenia gravis using nanodisc-incorporated acetylcholine receptor. Exp. Neurol. 2010, 225:320-327.
131. Bricarello D.A., Patel M.A., Parikh A.N. Inhibiting host-pathogen interactions using membrane-based nanostructures. Trends Biotechnol. 2012, 30:323-330.
132. Aizenberg J., Fratzl P. Biological and biomimetic materials. Adv. Mater. 2009, 21:387-388.
133. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
134. Denmeade S.R., Mhaka A.M., Rosen D.M., Brennen W.N., Dalrymple S., Dach I., Olesen C., Gurel B., Demarzo A.M., Wilding G., Carducci M.A., Dionne C.A., Moller J.V., Nissen P., Christensen S.B., Isaacs J.T. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med. 2012, 4. 140ra186.
135. Stephan M.T., Irvine D.J. Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials. Nano Today 2011, 6:309-325.
136. de Carvalho J.V., de Castro R.O., da Silva E.Z., Silveira P.P., da Silva-Januario M.E., Arruda E., Jamur M.C., Oliver C., Aguiar R.S., daSilva L.L. Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. PLoS One 2014, 9:e113691.
137. Inal J.M., Ansa-Addo E.A., Lange S. Interplay of host-pathogen microvesicles and their role in infectious disease. Biochem. Soc. Trans. 2013, 41:258-262.
138. Bhakdi S., Tranumjensen J. Damage to mammalian-cells by proteins that form transmembrane pores. Rev. Physiol. Biochem. Pharmacol. 1987, 107:147-223.
139. Steck T.L. The organization of proteins in the human red blood cell membrane. A review. J. Cell Biol. 1974, 62:1-19.
140. Lejeune A., Moorjani M., Gicquaud C., Lacroix J., Poyet P., Gaudreault R. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res. 1994, 14:915-919.
141. Hu C.M., Zhang L., Aryal S., Cheung C., Fang R.H., Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10980-10985.
142. Hu C.M., Fang R.H., Luk B.T., Chen K.N., Carpenter C., Gao W., Zhang K., Zhang L. 'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 2013, 5:2664-2668.
143. Luk B.T., Hu C.M., Fang R.H., Dehaini D., Carpenter C., Gao W., Zhang L. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014, 6:2730-2737.
144. Parodi A., Quattrocchi N., van de Ven A.L., Chiappini C., Evangelopoulos M., Martinez J.O., Brown B.S., Khaled S.Z., Yazdi I.K., Enzo M.V., Isenhart L., Ferrari M., Tasciotti E. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 2013, 8:61-68.
145. Fang R.H., Hu C.M., Luk B.T., Gao W., Copp J.A., Tai Y., O'Connor D.E., Zhang L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014, 14:2181-2188.
146. Copp J.A., Fang R.H., Luk B.T., Hu C.M.J., Gao W.W., Zhang K., Zhang L.F. Clearance of pathological antibodies using biomimetic nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:13481-13486.
147. Mortimer E.A. Immunization against infectious disease. Science 1978, 200:902-907.
148. Metz B., Kersten G.F., Hoogerhout P., Brugghe H.F., Timmermans H.A., de Jong A., Meiring H., ten Hove J., Hennink W.E., Crommelin D.J., Jiskoot W. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J. Biol. Chem. 2004, 279:6235-6243.
149. Cryz S.J., Furer E., Germanier R. Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae. Infect. Immun. 1982, 38:21-26.
150. Jones R.G.A., Liu Y., Rigsby P., Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J. Immunol. Methods 2008, 337:42-48.
151. Kennedy A.D., Bubeck Wardenburg J., Gardner D.J., Long D., Whitney A.R., Braughton K.R., Schneewind O., DeLeo F.R. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 2010, 202:1050-1058.
152. Adhikari R.P., Karauzum H., Sarwar J., Abaandou L., Mahmoudieh M., Boroun A.R., Vu H., Nguyen T., Devi V.S., Shulenin S., Warfield K.L., Aman M.J. Novel structurally designed vaccine for S. aureus alpha-hemolysin: protection against bacteremia and pneumonia. PLoS One 2012, 7:e38567.
153. Jang S.I., Lillehoj H.S., Lee S.H., Lee K.W., Lillehoj E.P., Hong Y.H., An D.J., Jeong W., Chun J.E., Bertrand F., Dupuis L., Deville S., Arous J.B. Vaccination with Clostridium perfringens recombinant proteins in combination with Montanide ISA 71 VG adjuvant increases protection against experimental necrotic enteritis in commercial broiler chickens. Vaccine 2012, 30:5401-5406.
154. Kirkham L.A., Kerr A.R., Douce G.R., Paterson G.K., Dilts D.A., Liu D.F., Mitchell T.J. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect. Immun. 2006, 74:586-593.
155. Hu C.M.J., Fang R.H., Luk B.T., Zhang L.F. Nanoparticle-detained toxins for safe and effective vaccination. Nat. Nanotechnol. 2013, 8:933-938.
156. Fonseca S.G., Ferreira A.M.M., Diniz C.R., Chavez-Olortegui C. Induction of neutralizing antibodies in mice immunized with scorpion toxins detoxified by liposomal entrapment. Braz. J. Med. Biol. Res. 1997, 30:883-886.
157. Freitas T.V., Diniz C.R., Frezard F. The use of liposomes as snake venom vehicles: application in protective immunization. J. Toxicol. Toxin Rev. 1998, 17:441-466.
158. Chavez-Olortegui C., Amara D.A., Rochat H., Diniz C., Granier C. In vivo protection against scorpion toxins by liposomal immunization. Vaccine 1991, 9:907-910.